Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
|Articles|January 31, 2013
A Wish List For Medicare
Advertisement
If you could make one change to Medicare, what would it be? Ask three former directors of the program and you’ll get plenty of ideas.
Bruce Vladeck, who was head of what was then known as the Health Care Financing Administration, or HCFA, for former President Bill Clinton, wants more market-based competition and less pricing set by Congress.
Read the full story:
Source: Kaiser Health News
Advertisement
Related to this article
Claims data show evidence of HIV virus in 5 of 2913 long-acting cabotegravir users and higher adherence vs oral therapy.
Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Most Medicaid unwinding losses were procedural. mPulse's SriVani Ganti explains how plans can keep eligible members.
Elagolix 150 mg was noninferior to dienogest 2 mg for reducing moderate-to-severe endometriosis pain in a phase 3 trial of 230 women in India.
Initial frontal fibrosing alopecia treatment was largely similar in Black and White patients, though tetracycline use was higher in Black patients.
Nearly half of patients with chronic HBV or HCV also had MASLD, tied to worse fatigue and quality of life.
Advertisement
Advertisement
Trending on AJMC
1
New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence
2
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
3
Biosimilar Entry Should Trigger a Fresh Look at Biologic Access
4
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
5